Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)

NCT00938314 is registered in ClinicalTrials.gov with Stem Cell Therapeutics Corp. as lead sponsor.

NCT NCT00938314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00938314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)
Lead sponsor
Stem Cell Therapeutics Corp.
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2009
Completion date
April 30, 2010
Enrollment
96 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

stroke